摘要
目的:观察舍雷肽酶肠溶片联合复方异丙托溴铵治疗慢性阻塞性肺疾病(COPD)急性加重期的临床效果。方法:COPD急性加重期患者138例随机分为观察组和对照组各69例。两组均给予常规治疗。对照组同时加用复方异丙托溴铵溶液2.5 ml,雾化吸入,tid;观察组在对照组基础上再加用舍雷肽酶肠溶片10 mg,po,tid。两组疗程均为14 d。观察两组临床疗效,比较治疗前后两组患者的肺功能[第1秒用力呼气量(FEV1)、第1秒用力呼气量占预计值百分比(FEV1%pred)、每分钟最大通气量占预计值百分比(MVV%pred)]、血气分析[氧分压(PaO2)、二氧化碳分压(PaCO2)、氧和指数(OI)]等指标和血清炎症因子[血清白三烯B4(LTB4)、C反应蛋白(CRP)、半乳糖凝集素-3(Gal-3)、降钙素原(PCT)]水平变化。结果:观察组临床有效率为92.75%,明显高于对照组的75.36%(P<0.05)。治疗后,两组患者各项肺功能和血气分析指标均较治疗前显著改善(P<0.05),且观察组上述指标均显著优于对照组(P<0.05);两组血清炎症因子水平均较前显著下降(P<0.05),且观察组的血清炎症因子水平均显著低于对照组(P<0.05)。结论:舍雷肽酶肠溶片联合复方异丙托溴铵治疗COPD急性加重期疗效理想,能明显减轻患者临床症状,改善肺功能,降低炎性因子水平。
Objective:To observe the clinical effect of seretidase enteric coated tablets combined with compound ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods:The patients(138 cases)with acute exacerbation of COPD were randomly divided into observation group and control group,69 cases in each group.Both groups were given conventional treatment.The control group was also given compound ipratropium bromide solution 2.5ml,aerosol inhalation,tid;the observation group was given seretidase enteric coated tablets 10mg,po,tid on the basis of the control group.The course of treatment was 14 days in both groups.The clinical effects of the two groups were observed,Pulmonary function(FEV1,FEV1%pred,MVV%pred),blood gas analysis indexes(PaO2,PaCO2,OI)and serum inflammatory factors(LTB4,CRP,Gal-3,PCT)were compared between the two groups before and after treatment.Results:The clinical effective rate of the observation group was 92.75%,which was significantly higher than that of the control group(75.36%)(P<0.05).After treatment,the pulmonary function and blood gas analysis indexes of the two groups were significantly improved(P<0.05),and the above indexes of the observation group were significantly better than those of the control group(P<0.05);the serum inflammatory factor levels of the two groups were significantly decreased(P<0.05),and the serum inflammatory factor levels of the observation group were significantly lower than those of the control group(P<0.05).Conclusion:Seretidase enteric coated tablets combined with compound ipratropium bromide is effective in the treatment of acute exacerbation of COPD,which can significantly reduce the clinical symptoms,improve pulmonary function and reduce the level of inflammatory factors.
作者
范道圣
王登
熊汉忠
Fan Daosheng;Wang Deng;Xiong Hanzhong(Department of Respiratory,Ezhou Central Hospital,Hubei Ezhou 436000,China)
出处
《中国药师》
CAS
2020年第10期1963-1966,共4页
China Pharmacist
关键词
舍雷肽酶肠溶片
复方异丙托溴铵
慢性阻塞性肺疾病急性加重期
疗效
Seretidase enteric coated tablets
Compound ipratropium bromide
Acute exacerbation of chronic obstructive pulmonary disease
Curative effect
